1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
XOMA Corporation

XOMA Corporation

XOMAP
XOMA CorporationUS flagNASDAQ Global Market
25.51
USD
+0.05
- -
307.74MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
35
19
55
6
53
5
18
29
38
6
5
10
12
8
Operating Margin (%)
-163.26
-433.31
-64.97
-1,024.3
38.87
-282.05
-21.15
42.25
45.94
-288.93
-493.13
-391.15
97.63
65.01
Depreciation Expense
3
2
2
1
- -
- -
- -
- -
- -
- -
1
- -
3
3
Net Income, GAAP
-124
-38
-21
-54
15
-13
-2
13
16
-17
-41
-14
32
34
Effective Tax Rate (%)
- -
- -
- -
- -
10.22
- -
- -
- -
0.57
- -
- -
- -
0.32
0.31
Profit Margin (%)
-349.94
-203.02
-37.16
-962.08
27.7
-251.8
-10.79
45.25
41.4
-283.79
-858.15
-135.23
271.97
441.79
Working Capital
97
47
49
-5
37
42
51
76
84
54
150
101
82
86
LT Debt
35
16
43
25
15
22
28
13
- -
- -
119
107
117
108
Total Equity
-4
3
-2
-47
6
19
44
86
142
124
89
62
84
113
Return on Invested Capital (%)
- -
- -
- -
- -
204.82
- -
- -
- -
13.95
- -
- -
- -
5.72
2.27
Return on Capital (%)
- -
- -
- -
- -
-1.36
- -
- -
- -
-1.4
- -
- -
- -
-4.05
-4.26
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
17
15
16
LT Borrowings
94
96
89
LT Finance Leases
21
20
20
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
111
117
119
Cash, Cash Equivalents & STI
47
83
86
Accounts Receivable, Net
4
5
5
Inventories
- -
- -
- -
Total Current Liabilities
28
35
33
Payables & Accruals
7
9
7
ST Debt
17
15
16
Deferred Revenue
1
1
1

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
231.61%
5.7%
35.6%
Free Cash Flow
-94.43%
92.58%
29.68%
Net Income, GAAP
-146.14%
-89.27%
-329.45%
Sales/Revenue/Turnover
102.72%
10.7%
14.09%
Total Cash Common Dividend
- -
- -
-94.72%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
6
1
2
10
2025
4
5
1
1
12
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Owen Hughes Jr.
Full Time Employees
13
Sector
Healthcare
Industry
Biotechnology
Address
2200 Powell Street EmeryVille CA United States of America 94608
IPO Date
Dec 16, 2020
CIK
0000791908
Website
xoma.com
Similar Companies
Applied Therapeutics, Inc. (APLT)
La Jolla Pharmaceutical Company (LJPC)
Relay Therapeutics, Inc. (RLAY)
Traws Pharma, Inc. (TRAW)
Spexis AG (PPHOF)
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)
Business
XOMA Royalty Corporation (NASDAQ: XOMA), formerly XOMA Corporation, operates as a biotechnology royalty aggregator that acquires economic rights to future milestone and royalty payments from pre-commercial clinical candidates and commercial therapies licensed to pharmaceutical and biotechnology partners; its portfolio encompasses over 120 such assets spanning multiple therapeutic areas and development stages, including commercial products like VABYSMO (faricimab-svoa) for neovascular age-related macular degeneration and diabetic macular edema, OJEMDA (tovorafenib), MIPLYFFA (arimoclomol), XACIATO (clindamycin phosphate vaginal gel 2%), IXINITY (coagulation factor IX recombinant), and DSUVIA (sufentanil sublingual tablet), as well as early- to mid-stage investigational candidates such as those from partners including Roche, Day One Biopharmaceuticals, Zevra Therapeutics, Rezolute, Gossamer Bio, and Takeda; the company targets development-stage assets with blockbuster potential from well-capitalized partners and royalties on therapies addressing specific patient populations, employing a portfolio approach to mitigate single-asset risk while operating a capital-efficient structure where partners bear all R&D costs. Founded in 1981 and headquartered in Emeryville, California, XOMA Royalty conducts its activities primarily in the United States, Asia Pacific, Europe, and Switzerland, providing non-dilutive, non-recourse funding to sellers for advancing drug candidates or general corporate purposes. Recent developments include the completion of acquisitions for Turnstone Biologics at $0.34 per share plus a contingent value right and HilleVax at $1.95 per share plus a contingent value right; announcements of acquisitions for LAVA Therapeutics, securing interests in partnered assets PF-08046052 (Pfizer) and JNJ-89853413 (Johnson & Johnson), and Mural Oncology at $2.035 to $2.24 per share expected in Q4 2025; acting as structuring agent for XenoTherapeutics' acquisition of ESSA Pharma; a financing arrangement raising up to $140 million with Blue Owl Capital to support repurchases and further acquisitions; and portfolio advancements such as Zevra Therapeutics' MAA submission for arimoclomol in Niemann-Pick Type C, Rezolute's Phase 3 topline data expectations, and Gossamer Bio's Phase 3 trial progress.

Company News

APIChat

  • defenseworld.net

    XOMA (NASDAQ:XOMAP) Stock Price Down 1.5% – Time to Sell?